Publicaciones en colaboración con investigadores/as de Pfizer (United States) (8)

2016

  1. An integrated analysis of the efficacy and safety of Desvenlafaxine in the treatment of major depressive disorder

    International Clinical Psychopharmacology, Vol. 31, Núm. 3, pp. 134-146

2015

  1. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors

    Annals of General Psychiatry, Vol. 14, Núm. 1

  2. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice

    Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340

  3. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms

    International Clinical Psychopharmacology, Vol. 30, Núm. 5, pp. 265-271

2013

  1. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain

    Actas Espanolas de Psiquiatria, Vol. 41, Núm. 3, pp. 164-174

  2. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain

    Social Psychiatry and Psychiatric Epidemiology, Vol. 48, Núm. 6, pp. 985-996

2012

  1. Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: Findings from the observational ADAN study

    Clinical Practice and Epidemiology in Mental Health, Vol. 8, pp. 158-168

  2. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain

    ClinicoEconomics and Outcomes Research, Vol. 4, Núm. 1, pp. 157-168